The Journal of infectious diseases · 2025
Efficacy and Safety of Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Infection Among People Living With HIV.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Jinzhi, Wang Ying, Chen Liyu, Feng Ping, Song Xiaona, Shen Yalin, Ma Fanghua, Tay Alfred C Y, Marshall Barry J, Tang Hong, Li Hong
Аннотация
BACKGROUND: Antiretroviral therapy (ART) has significantly increased the life expectancy of people living with human immunodeficiency virus (PLWH), resulting in a growing need for the treatment of Helicobacter pylori infections in this population. H. pylori treament among PLWH who are on ART can be challenging due to potential drug-drug interactions (H. pylori eradication drugs interact with ART drugs). This study aimed to evaluate the efficacy and safety of vonoprazan-amoxicillin (VA) dual therapy for H. pylori infection among PLWH.
METHODS: A total of 201 treatment-naive, H. pylori--positive PLWH on ART were enrolled to receive vonoprazan (20 mg twice daily) plus amoxicillin (1000 mg 3 times daily) for 14 days. H. pylori eradication status was assessed using the urease breath test ≥4 weeks after treatment. Patient compliance and adverse events (AEs) were recorded.
RESULTS: Of the 201 participants, 181 (90.0%) completed the treatment course. Nineteen patients were lost to follow-up, and 1 discontinued treatment due to a rash. The eradication rates were 74.6% (150 of 201) by intention-to-treat analysis, 82.9% (150 of 181) by modified intention-to-treat analysis, and 90.6% (145 of 160) by per-protocol analysis. AEs occurred in 10 patients (5.0%), including abdominal distension in 5 and abdominal pain, nausea, diarrhea, fatigue, and rash, each occurring in 1 patient. Most AEs were mild and resolved spontaneously after treatment. Good compliance (odds ratio, 1.03 [95% confidence interval, 1.01-1.11]; P < .001) was independently associated with the efficacy of VA for H. pylori eradication.
CONCLUSIONS: VA dual therapy as a first-line treatment for H. pylori infection among PLWH on ART demonstrates good efficacy and safety.
CLINICAL TRIALS REGISTRATION: ChiCTR2400085762.
METHODS: A total of 201 treatment-naive, H. pylori--positive PLWH on ART were enrolled to receive vonoprazan (20 mg twice daily) plus amoxicillin (1000 mg 3 times daily) for 14 days. H. pylori eradication status was assessed using the urease breath test ≥4 weeks after treatment. Patient compliance and adverse events (AEs) were recorded.
RESULTS: Of the 201 participants, 181 (90.0%) completed the treatment course. Nineteen patients were lost to follow-up, and 1 discontinued treatment due to a rash. The eradication rates were 74.6% (150 of 201) by intention-to-treat analysis, 82.9% (150 of 181) by modified intention-to-treat analysis, and 90.6% (145 of 160) by per-protocol analysis. AEs occurred in 10 patients (5.0%), including abdominal distension in 5 and abdominal pain, nausea, diarrhea, fatigue, and rash, each occurring in 1 patient. Most AEs were mild and resolved spontaneously after treatment. Good compliance (odds ratio, 1.03 [95% confidence interval, 1.01-1.11]; P < .001) was independently associated with the efficacy of VA for H. pylori eradication.
CONCLUSIONS: VA dual therapy as a first-line treatment for H. pylori infection among PLWH on ART demonstrates good efficacy and safety.
CLINICAL TRIALS REGISTRATION: ChiCTR2400085762.